3Q markets preview; quantum computing; Makary’s first 100 days — a BioCentury podcast

China biotechs surge in 1H25, but rest of sector still has overhangs that are holding back sentiment

Chinese biotech was the lone bright spot for the biopharma financial markets in 1H25, as macro concerns about the most favored nation pricing policy and FDA weigh on the prospects for biotech elsewhere. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the positives — and negatives — impacting investor sentiment headed into the second half of the year.

The team also discuss where the quantum computing revolution could have its biggest impact on drug development, and review the proposals and accomplishments of FDA Commissioner Marty Makary over his first 100 days in office.